Cargando…
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
BACKGROUND: Current treatment of ovarian cancer patients with chemotherapy leaves behind a residual tumor which results in recurrent ovarian cancer within a short time frame. We have previously demonstrated that a single short-term treatment of ovarian cancer cells with chemotherapy in vitro resulte...
Autores principales: | Abubaker, Khalid, Luwor, Rodney B, Zhu, Hongjian, McNally, Orla, Quinn, Michael A, Burns, Christopher J, Thompson, Erik W, Findlay, Jock K, Ahmed, Nuzhat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025194/ https://www.ncbi.nlm.nih.gov/pubmed/24886434 http://dx.doi.org/10.1186/1471-2407-14-317 |
Ejemplares similares
-
Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden
por: Abubaker, Khalid, et al.
Publicado: (2014) -
Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden
por: Abubaker, Khalid, et al.
Publicado: (2013) -
Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer
por: Chan, Emily, et al.
Publicado: (2018) -
Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors
por: Latifi, Ardian, et al.
Publicado: (2012) -
Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer
por: Samardzija, Chantel, et al.
Publicado: (2016)